This inventor holds 2 USPTO granted patents. Top assignees: Institute for Basic Science, Korea Advanced Institute of Science and Technology. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 99 
2 out of 2,792 
Years Active: 2022-2025
Title: Jin-Sung Park: Innovator in Anti-Angiopoietin-2 Antibodies
Introduction
Jin-Sung Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of anti-angiopoietin-2 antibodies. With a total of 2 patents, his work focuses on therapeutic solutions for diseases associated with abnormal blood vessels.
Latest Patents
One of Jin-Sung Park's latest patents involves anti-angiopoietin-2 antibodies that induce Tie2 activation. This invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2) and includes humanized anti-Ang2 antibodies derived from them. The anti-Ang2 antibodies serve a dual purpose by activating the Tie2 receptor while neutralizing Ang2. These antibodies have shown the ability to normalize abnormal and pathological blood vessels, demonstrating therapeutic efficacy against various diseases and disorders linked to such conditions. Additionally, the invention provides an angiogenesis inhibitor and a composition for treating diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which includes the antibody as an active ingredient. It also offers a composition for diagnosing diseases related to Ang2 inhibition and Tie2 activation.
Career Highlights
Jin-Sung Park has worked at notable institutions such as the Institute for Basic Science and the Korea Advanced Institute of Science and Technology. His research has significantly advanced the understanding of angiogenesis and its implications in various medical conditions.
Collaborations
Throughout his career, Jin-Sung Park has collaborated with esteemed colleagues, including Gou Young Koh and Jeomil Bae. These partnerships have contributed to the success of his research and innovations.
Conclusion
Jin-Sung Park is a distinguished inventor whose work on anti-angiopoietin-2 antibodies has the potential to transform therapeutic approaches for diseases related to abnormal blood vessels. His contributions to biotechnology continue to pave the way for future innovations in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile